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ABSTRACT 
Background: HLA haploidentical bone marrow transplantation is a treatment option in patients with 
hematological malignancies who have no available HLA matched donor, but is limited by conditioning 
regimen toxicity, graft failure, relapse and graft versus host disease.  
Aims: To demonstrate safety and efficacy of haploidentical bone marrow transplantation with 
nonmyeloablative conditioning and high-dose post-transplant cyclophosphamide in adult patients with 
leukaemia or lymphoma. 
Methods: 12 patients, median age of 51 years, underwent transplantation with T cell replete bone marrow 
from a haplotype matched relative. The conditioning regimen consisted of cyclophosphamide, fludarabine, 
and low-dose TBI. Post-transplant immunosuppression consisted of a single dose of cyclophosphamide 50 
mg/kg on day 3, followed by oral tacrolimus and mycophenolate mofetil. Outcomes reported are overall 
survival, engraftment and chimerism, toxicity, and clinical outcome. 
Results: All patients had neutrophil recovery (median 14.5 days), and 11 of 12 had platelet engraftment 
(median 17 days). Two patients had autologous reconstitution. Seven of 9 assessable patients had complete 
donor chimerism. Four patients had grade II-III GvHD, and none had grade IV GvHD. Four 
patientsdeveloped limited stage chronic GvHD.  Five patients with AML relapsed. Two patients died of non-
relapse causes, both from other malignancies, and 5 patients remain alive and relapse free. Median overall 
survival was 324 days (range 88-1163). 
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Conclusion: This regimen is feasible and well-tolerated in older patients with high risk leukemia or 
lymphoma, with minimal short-term toxicity, and low rates of GVHD. The proportion of disease-free 
survivors indicates a graft versus malignancy effect is present in survivors.  
Keywords: hematological malignancy, bone marrow transplant, haploidentical, post-transplant 
cyclophosphamide 
 
BACKGROUND 
Haploidentical allogeneic hematopoietic cell transplantation (HCT) is currently under investigation as a 
treatment strategy for high risk hematological malignancies and for those who otherwise lack a suitable 
donor. The optimum donor for allogeneic HCT is generally regarded as a matched sibling,1 however 
approximately 70% of potential HCT recipients have no sibling donor, and the chance of finding an 
appropriately matched unrelated donor (MUD) from international marrow donor registries is highly 
dependent on ethnicity.2 Unrelated umbilical cord blood (UCB) banks have increased the number and 
speed of donor unit availability with less stringent HLA-matching requirements,3 but are limited in the adult 
setting primarily due to inadequate cell dosing, though this may be partly overcome by the use of multiple 
UCB units.4 In contrast every patient shares at least one HLA haplotype with each parent and any children, 
and has a 75% chance of sharing at least one HLA haplotype with each sibling. The use of HLA 
haploidentical related donors would provide virtually all patients with a potential donor irrespective of 
ethnicity, thus extending allogeneic HCT to over 90% of those who could potentially benefit.5 The main 
challenges involve overcoming the dual problems of graft-versus-host disease (GvHD) and graft rejection 
due to HLA disparity. 
 Several broad approaches to haploidentical HCT have been evaluated. Myeloablative conditioning 
therapy combined with heavily T cell depleted grafts containing ‘mega-doses’ of CD34+ progenitor cells 
have proved feasible,6-8 but with delayed immune reconstitution and increased infection risk. Non-
myeloablative (NMA) conditioning approaches for haploidentical transplantation have also been 
investigated to reduce conditioning regimen toxicity. One such approach has employed the combination of 
fludarabine, cyclophosphamide, and low dose total body irradiation (TBI) for conditioning therapy, with an 
unmanipulated T cell-replete bone marrow (BM) graft, and post-transplant immunosuppression with high 
dose cyclophosphamide.9, 10 The rationale for high-dose cyclophosphamide early after transplant is the 
immunological tolerance conferred by the ability of alkylator therapy to preferentially affect proliferating 
lymphocytes over resting cells, resulting in deletion of alloreactive T cells. This spares the non-proliferating 
graft T cells which contribute to immune reconstitution and anti-tumour activityin the longer term.11, 12 
Preclinical studies validated the safety of administrating high-dose cyclophosphamide on day 3 post-
transplant,13 and early phase human trials using cyclophosphamide 50 mg/kg on day 3, or both days 3 and 4 
have now been published.10, 14 Using this regimen Luznik and colleagues10 demonstrated low rates of graft 
failure (13%), grade III-IV acute GvHD (6%) and chronic GvHD (22%). 
 We have adapted this protocol and report our experience over 2 years in transplanting 12 patients 
with poor-risk hematological malignancies who lacked matched related or unrelated donors.  
 
PATIENTS AND METHODS 
Patients: 
12 consecutive patients with poor-risk hematological malignancies underwent allogeneic HCT from a HLA 
haploidentical related donor at Westmead Hospital from April 2008 to November 2010. All patients gave 
informed consent for treatment.Patients were considered eligible for haploidentical HCT if no suitable HLA-
matched sibling or unrelated donor was available, where autologous HCT was inappropriate, and had 
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poorrisk hematologic malignancy. Patient median age was 51 years (range 27-62) (Table 11). Nine patients 
had acute myeloid leukaemia (AML) with a high risk for relapse on the basis of prior relapse (n=2), 
secondary or therapy related AML(n=2), persistent cytogenetic abnormality following induction 
chemotherapy (n=1), or poor risk cytogenetics (n=4). Two patients had follicular lymphoma, one 
transplanted for progressive disease despite multiple prior lines of treatment, and the other with marrow 
failure following the most recent line of chemotherapy. One patient had chronic myeloid leukemia (CML) in 
chronic phase, refractory to tyrosine kinase inhibitor therapy, with a T315I BCR-ABL mutation (Table 1). 
Donors were selected after review of HLA typing data for available family members. Criteria for selection of 
haploidentical relatives included availability, age and fitness for marrow harvest under general anesthesia, 
CMV serostatus and ABO blood group matching with the patient. Kir typing was not done. 
Transplant protocol: 
The transplant schedule was adapted from that described by Luznik and colleagues.10 Conditioning therapy 
consisted of cyclophosphamide 14.5 mg/kg/day ivi + mesna 14.5mg/kg/day on days -6 and -5, fludarabine 
30 mg/m2/day ivi on days -6 to -2, and total body irradiation with a single fraction of 200cGy on day -1. 
Donor bone marrow was harvested under general anaesthetic aiming for a minimum total nucleated cell 
(TNC) count of 2 x 108 per kg recipient weight. In major ABO-mismatched transplants the graft was red-cell 
depleted using a Cobe 2991 cell processor (CaridianBCT, Lakewood, Co, USA). T cell depletion or other 
manipulation of the marrow was not performed. Monoclonal or polyclonal anti-T cell preparations were 
not used pre- or post-transplant. 
 Post-transplant prophylaxis against GvHD consisted of cyclophosphamide 50 mg/kg ivi over 60 
minutes on day +3, with mesna 50 mg/kg/day as a 24 hour infusion, followed by tacrolimus 2mg bd po and 
mycophenolate mofetil (MMF) 15 mg/kg/dose tds po starting on day +4. In the absence of GvHD, MMF was 
weaned from day +30 and tacrolimus from day +84. 
Supportive care: 
Granulocyte colony-stimulating factor (G-CSF) 5 µg/kg/day was administered from day +4 until neutrophil 
recovery > 1.0 x109/L.  Infection prophylaxis was as standardly used at our institution for related allogeneic 
transplants, and consisted of ganciclovir 5 mg/kg bd days -8 to -1 in those recipients who were 
cytomegalovirus seropositive, cotrimoxazole 160/800 mg bd from day -8 to day -1, metronidazole 400 mg 
po tds, ciprofloxacin 750 mg bd, acyclovir 800 mg bd, and fluconazole 400 mg starting day 0. Penicillin V 
250 mg bd and cotrimoxazole 160/800 mg bd twice weekly were commenced on day +28. 
Chimerism analysis: 
Flow-sorted peripheral blood T cells or peripheral blood mononuclear cells (PBMCs) were analysed for 
chimerism using polymerase chain reaction (PCR) on highly polymorphic short tandem repeat (STR) 
markers. Complete engraftment was defined as the lack of recipient specific STR on polyacrylimide gel 
analysis, with mixed chimerism detectable when greater than 5% recipient STR present. In one patient with 
a sex-matched graft and without an informative STR marker graft rejection was confirmed by HLA-typing on 
peripheral blood mononuclear cells. 
Statistical methods: 
Engraftment and survival were analysed using the method of Kaplan-Meier. Survival outcomes were 
estimated using a close-out date of 30-6-11. 
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RESULTS 
Bone marrow grafts: 
Details of the HLA-matching, donor source and cell doses are shown in Table 1. Donors were either siblings 
(n=9) or children (n=3). HLA-matching at HLA-A, -B, and –DRB1 was either 3/6 (n=11), or 4/6 (n=1). The 
median bone marrow TNC count was 3.05 x 108/kg, (range 2.4-5.7), and median CD34+ dose infused was 
2.55 x 106/kg (range 1.3-4.8). 
Engraftment and chimerism: 
All 12 patients had sustained neutrophil recovery to > 0.5 x 109/L, at a median time of 14.5 days (range 4-
55). One patient failed to reach a platelet count >20 x109/L prior to death from relapse, the remainder 
showed platelet recovery at a median of 17 days post transplant (range 1-66). Five patients did not reach 
nadir platelet counts ≤ 20 x 109/L. One patient required no platelet transfusions, and3 others avoided both 
red cell and platelet transfusions. 
 Chimerism status was assessable in 9 patients. Two patients had early relapse and no post 
transplant chimerism testing was performed. One patient had no informative STR marker available, and 
autologous reconstitution was demonstrated by repeat HLA typing. One patient had 90% donor T cell 
chimerism at day 31, but subsequent autologous reconstitution was shown on day 73, while another had 
persistent mixed chimerism to day 123, then relapsed. The remaining 7 patients achieved complete donor T 
cell chimerism. 
Transplant toxicity: 
The procedure was well tolerated, with all patients surviving to discharge and no patients requiring ICU 
admission or parenteral nutrition. No patients experienced hepatic sinusoidal-obstructive syndrome, 
haemorrhagic cystitis or grade III-IV mucositis. The median length of hospital stay was 25 days (range 11-
52). Bacteraemias post transplant were detected in 4 patients (33%), central line-related coagulase 
negative staphylococcus in 3 cases, and a skin contaminant bacillus species in the other case, but no 
patients developed septic shock or required inotropic or ventilator support. Only 3 out of 9 at risk patients 
required pre-emptive CMV therapy, all with a complete response. There were no proven or probable 
invasive fungal infections, although one patient was treated for aspergillus on the basis of a sputum isolate, 
in the absence of CT chest signs (Table 2).  
 Four out of 12 patients developed grade II-III acute GvHD, all responding to corticosteroids and 
tacrolimus, but no patients experienced grade IV acute GvHD. Limited stage chronic GvHD occurred in 4 out 
of 11 evaluable patients, with no patient developing extensive cGvHD. 
Transplant-related mortality at 1 year was 16%, with both patients dying from secondary 
malignancy at 220 and 256 days post-transplant respectively. 
Relapse: 
Overall 5 patients had relapse of their hematologic malignancy, all with AML. Four subsequently died of 
relapse, while the other died in CR2 from acute GvHD following umbilical cord blood transplantation.  
Survival: 
With a median follow up of 685 days post transplant (minimum follow up 231 days) the median overall 
survival for the group is 324 days (range: 88–1163) (Fig. 1). The cumulative incidence of mortality at day 
100 is 8%, with one patient succumbing to relapse after 88 days, while the mortality at 1 year is 50% (5 of 
10 evaluable patients), with 3 dying of relapse, and 2 of secondary malignancies. Five of 12 patients are 
alive and relapse-free, with median follow up of 384 days (range 231-1163).  
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 One patient was transplanted for TKI refractory CML in chronic phase with a T315I mutation. 
Dasatinib was ceased on day -9. Baseline qPCR for BCR-ABL was 11.2%, but by day 31 the level had reduced 
to 0.0027%, and was undetectable at day 76. She remains in complete molecular response with 
undetectable BCR-ABL and no GvHD after a follow up 384 days. 
 
DISCUSSION 
This report demonstrates the feasibility of the use of unmanipulated T cell replete bone marrow 
transplantation from HLA-haploidentical related donors following a reduced intensity conditioning regimen 
in a group of patients with high risk hematological malignancies. The use of a high dose of 
cyclophosphamide following infusion of the donor bone marrow to deplete alloreactive donor T cells 
enabled stable engraftment in the majority and prevented serious GVHD - obviating the need for T cell 
depletion of the graft and reducing the risks of immunosuppression and infection.  The regimen was well-
tolerated, with minimal mucositis and no serious bacteraemias, enabling its use in older patients who 
lacked matched related or unrelated donors, and for whom a myeloablative unrelated cord blood 
transplant was contra-indicated. In addition, since it requires no graft manipulation or in vivo T cell 
depletion, it is simple, less costly, and practical to implement, particularly where cost constraints may 
apply.  
Our results are consistent with the reported experience from the USA using the same regimen. 
Seventeen percent (2 out of 12) of our patients had graft loss and autologous reconstitution, compared 
with 20% (2 out of 10 patients) in the original Phase 1 trial reported by O’Donnell and colleagues14 and 14% 
(9 out of 66 patients) in the subsequent report by Luznik and colleagues.10 
The overall cumulative incidence of relapse in our cohort is 42% (5 of 12 patients) and non relapse 
mortality is 17% (2 of 12 patients), compared to that of Luznik of 51% and 15% respectively at 1 year. The 
risk of post-transplant relapse is strongly influenced by pre-transplant disease type and status. Two of our 
patients relapsed early post transplant, both with advanced AML. Given the relatively low intensity of the 
conditioning regimen, this protocol may not be appropriate for patients at high risk of early relapse. We are 
implementing a modified protocolusing a more intensive conditioning regimen using fludarabine and 
intravenous busulfan for such patients. 
 Two patients died while in remission of their hematological malignancy from other malignancies. 
One patient had a malignant melanoma resected several years previously with no evidence of recurrence, 
however presented with an aggressive metastatic melanoma post HCT. The other patient had been a heavy 
smoker for many years, and succumbed very rapidly with multi-organ failure at approximately 7 months 
post transplant. Post-mortem examination subsequently revealed widespread adenocarcinoma of probable 
lung origin. It is highly likely that both malignancies were present prior to transplant and it is possible that 
their presentation was hastened by the post-transplant immunosuppression.15 
 One of our patients was transplanted for TKI refractory CML with a T315I mutation. Allogeneic 
transplantation results have been published in this group with long term survivors reported.16, 17 Our early 
results with a haploidentical family donor are encouraging, with a complete molecular response from day 
71, and no significant GvHD to date. In the absence of an alternate novel agent, clinical trial, or suitable 
matched donor, this approach may be a viable alternative for this patient group without other options.  
  The choice of haploidentical donors or unrelated umbilical cord blood (UCB) units for allogeneic 
transplantation where no HLA-matched donor is available is currently being questioned. Parallel phase 2 
studies of haploidentical and double UCB transplantation were recently published.18 The outcomes of 
haploidentical transplantation using NMA conditioning and post-transplant cyclophosphamide were 
equivalent to RIC UCB in terms of survival and GvHD rates, and indeed were comparable to registry 
outcomes for HLA-matched RIC HCT. The outcomes of unrelated UCB transplantation using myeloablative 
conditioning at our institution have been published.19.20 For UCB transplants 5 out of 11 patients died within 
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2 months post transplant from transplant related complications, largely as a result of prolonged time to 
neutrophil engraftment, and there did not appear to be a significant improvement in survival using 2 versus 
1 UCB units. Our results for haploidentical RIC HCT appear safer, and given the ease and speed of 
identifying haploidentical relatives, and the contrasting expense and complexity of unrelated cord blood 
searches and procurement, this approach seems more amenable, particularly to older high risk patients. 
 In summary we report the outcome for 12 patients with poor-risk haematologic malignancies 
having haploidentical allogeneic HSCT, demonstrating low rates of transplant morbidity in terms of 
infections and GvHD, low NRM, and acceptable rates of graft failure and relapse  in this high risk cohort. 
This reduced intensity haploidentical approach appears simple and feasible, and extends the availability of 
a potentially curable treatment in a patient group with limited therapeutic options. Additional measures, 
including outpatient conditioning, modification of conditioning regimen dosing, post-transplant donor 
lymphocyte infusion (DLI) or the use of PBSC rather than BM (which is under investigation in our institution) 
may be necessary to improve outcomes in patients at high risk of relapse. 
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Table 1: Patient and graft details 
 
BMT number Gender Age (years) Diagnosis Disease Status (comments) Donor 
HLA 
Match
†
 
CMV 
Donor/Recipient 
Total Nucleated Cell 
Dose (x10
8
/kg) 
CD34 Dose 
(x10
6
/kg) 
654 F 50 AML CR2 Sister 4 of 6 Pos/Pos 2.6 1.9 
663 M 53 NHL 
PR3 (Multiply relapsed FL, prior 
autograft 2006) 
Brother 3 of 6 Pos/Pos 3.7 1.7 
664 M 56 AML CR1 (Preceding myelodysplasia) Brother 3 of 6 Pos/Pos 2.6 1.8 
687 M 50 AML 
CR1 (Chemo/radiotherapy 2007 for  
throat ca) 
Brother 3 of 6 Pos/Pos 5.7 2.9 
692 F 56 AML CR1 (Monosomal karyotype) Sister 3 of 6 Pos/Pos 3.2 2.6 
703 M 59 NHL 
CR2 (Marrow failure following 
chemotherapy) 
Brother 3 of 6 Neg/Pos 3 1.3 
729 M 48 AML 
CR1 (Persistent cytogenetic 
abnormality post induction) 
Son 3 of 6 Pos/Pos 2.9 2.5 
739 M 27 AML CR1 (Complex cytogenetic abnormality) Brother 3 of 6 Pos/Pos 3.1 3.7 
744 M 49 AML 
PR1 (Reinduction failure following 
relapse) 
Brother 3 of 6 Pos/Neg 2.9 1.9 
761 F 53 CML 
Chronic phase (TKI refractory - T315I 
mutation) 
Daughter 3 of 6 Neg/Neg 5.5 4.8 
775 F 35 AML CR1 (Complex cytogenetic abnormality) Brother 3 of 6 Neg/Neg 4.4 3.7 
791 F 62 AML CR1 (Monosomy 7) Son 3 of 6 Pos/Pos 2.4 2.6 
  Median 51         Median (range) 3.05 (2.4-5.7) 2.55 (1.3-4.8) 
 
†
Matching at HLA loci A, B, and DRB1.CR: complete remission; PR: partial remission; FL: follicular lymphoma; TKI: tyrosine kinase inhibitor; HLA: human leukocyte antigen 
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Table 2: Transplant outcomes 
 
BMT, n Infections  
Acute 
GVHD 
(grade) 
Chronic GVHD 
Disease status Patient status Cause of death 
Survival 
(days) 
Stage Severity 
654     NE NE Relapsed Deceased Relapse 88 
663 
Aspergillus in sputum, no 
CT changes, treated. 
I Limited Mild CR Alive 
 
1163 
664 CMV reactivation I Limited Mild CR Alive 
 
1112 
687 Nil Nil Nil Nil Relapsed
1 
Deceased Relapse 1041 
692 Nil II Limited Moderate Relapsed Deceased Relapse 285 
703 VZV II Nil Nil CR Deceased Melanoma 256 
729 CMV reactivation I Nil Nil CR Deceased 
Lung 
adenocarcinoma 
220 
739 Nil Nil Nil Nil Relapsed
 
Deceased 
GvHD following 
UCB HCT
2
 
384 
744 Nil Nil Nil Nil Relapsed Deceased Relapse 234 
761 Nil Nil Nil Nil CR
3
  Alive 
 
363 
775 RSV  II Nil Nil CR Alive 
 
384 
791 CMV reactivation III Limited Mild CR Alive 
 
231 
              Median 324 
 
1
Autologous reconstitution, then later relapse day 712. 
2
Autologous reconstitution then relapse day 181,received UCB HCT in CR2, then succumbed with 
GvHD.
3
Baseline BCR-ABL:11.2%, day 30: 0.0027%, and sustained complete molecular response by day 77. NE, not evaluable; CMV, cytomegalovirus; VZV, 
varicella zoster virus; RSV, respiratory syncitial virus; CR, complete remission 
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Figure 1: Overall survival curve. 
 
 
